BR112013004926A2 - anti-c-met antibody and methods for using it - Google Patents
anti-c-met antibody and methods for using itInfo
- Publication number
- BR112013004926A2 BR112013004926A2 BR112013004926A BR112013004926A BR112013004926A2 BR 112013004926 A2 BR112013004926 A2 BR 112013004926A2 BR 112013004926 A BR112013004926 A BR 112013004926A BR 112013004926 A BR112013004926 A BR 112013004926A BR 112013004926 A2 BR112013004926 A2 BR 112013004926A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- antibodies
- met antibody
- cells
- cell surface
- Prior art date
Links
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
anticorpo anti-c-met e métodos para utilização do mesmo. os anticorpos que ligam a c-met são fornecidos aqui, bem como composições relacionadasl e métodos do uso. os métodos do uso abrangem a terapia de câncer e a diagnóstica. em certas modalidades, os anticorpos ligam o antígeno de superfície celular mamífero (p.ex., o antígeno de superfície celulars cancerosas). os anticorpos também podem ser endocitados para ligar a células. o que de células pode ser visado pelos anticorpos incluem carcinomas, tais como aqueles em pulmão, rim, fígado, estômago, peito, e cérebro, etc.anti-c-met antibody and methods for using it. c-met binding antibodies are provided herein, as well as related compositions and methods of use. The methods of use include cancer therapy and diagnosis. In certain embodiments, antibodies bind to mammalian cell surface antigen (e.g., cancer cell surface antigen). Antibodies can also be endocyted to bind to cells. What cells may be targeted by antibodies include carcinomas, such as those in lung, kidney, liver, stomach, chest, and brain, etc.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40227810P | 2010-09-03 | 2010-09-03 | |
| PCT/US2011/049763 WO2012030842A2 (en) | 2010-09-03 | 2011-08-30 | Anti-c-met antibody and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013004926A2 true BR112013004926A2 (en) | 2016-07-05 |
Family
ID=56268417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013004926A BR112013004926A2 (en) | 2010-09-03 | 2011-08-30 | anti-c-met antibody and methods for using it |
Country Status (1)
| Country | Link |
|---|---|
| BR (1) | BR112013004926A2 (en) |
-
2011
- 2011-08-30 BR BR112013004926A patent/BR112013004926A2/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR089178A1 (en) | ANTI-IL-36R ANTIBODIES | |
| UY32971A (en) | PROTEINS OF UNION TO THE ANTIGEN OF HUMAN IL-23 | |
| BR112015014751A2 (en) | human anti-tau antibodies | |
| AR088941A1 (en) | ANTI-FGFR2 ANTIBODIES AND THEIR USES | |
| BRPI0613770A2 (en) | anti-cd26 antibodies and methods of use of these | |
| EA201590671A1 (en) | COMBINATION OF ANTIBODIES TO KIR AND ANTIBODIES TO PD-1 FOR THE TREATMENT OF MALIGNANT TUMOR | |
| BR112012023010A2 (en) | "antibody or antigen binding fragment thereof which specifically binds to cd37, immunoconjugate comprising them, use of said antibody, fragment and immunoconjugate, composition comprising them, kit, isolated cell, as well as in vitro method for inhibiting growth" of a cell expressing cd37 " | |
| CL2015002526A1 (en) | Anti-ox40 antibodies and methods of use thereof (divisional of 545-13). | |
| BR112019014615A2 (en) | CHEMICAL ANTIGEN RECEPTORS AGAINST AXL OR ROR2 AND METHODS OF USE OF THE SAME | |
| BR112014007382A2 (en) | anti-erbb3 antibodies and their uses | |
| MX2018008680A (en) | Tdp-43 specific binding molecules. | |
| EA201390472A1 (en) | NEW MOLECULES CONNECTING WITH EGFR AND THEIR IMMUNOCONJUGATES | |
| CL2013002203A1 (en) | Antigen binding molecule (abm) that binds to the human carcinoembryonic antigen (cea) membrane bound; membrane binding antibody to cea; polynucleotide that encodes them; vector; host cell; composition comprising the abm or the antibody; and its use to treat a cancer that expresses abnormal levels of cea. | |
| EA201490932A1 (en) | Binding Molecules for VSMA and CD3 | |
| MX2011006422A (en) | Human anti-alpha-synuclein autoantibodies. | |
| ECSP14001249A (en) | IMMUNOBINDERS TARGETED AGAINST TNF | |
| CL2008002015A1 (en) | Hepatocyte growth factor (hgf) anti-receptor antibody / c-met receptor; hybridoma that produces it; nucleic acid encoding it; vector and host cell that includes them; production procedure; composition that understands them; its use to treat cancer; and in vitro diagnostic method | |
| BR112014019116A8 (en) | KIT, ANTIBODY MOLECULES, PHARMACEUTICAL COMPOSITION, TREATMENT METHODS, USES, VECTOR, HOST CELL AND METHOD OF PRODUCTION OF AN ANTIBODY MOLECULE | |
| MX2014011066A (en) | Novel binding molecules with antitumoral activity. | |
| BR112013005145A2 (en) | anti-cxcl13 antibodies and methods for their use | |
| AR090884A1 (en) | ANTI-GCC ANTIBODY MOLECULES AND USE OF THE SAME TO PROVIDE SUSCEPTIBILITY TO GCC DIRECTED THERAPY | |
| EA200702361A1 (en) | ANTIBODIES AGAINST csPCNA ISOFORMS AND THEIR APPLICATION | |
| AR080680A1 (en) | BASIGIN UNION PROTEINS | |
| ECSP088636A (en) | ANTIGENS OF DES-N-ACETYL-SIALIC ACID, ANTIBODIES FOR THE SAME, AND METHODS OF USE IN CANCER THERAPY | |
| TR201909747T4 (en) | Transfer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A E 5A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |